Patient passed away [death].Bilateral primary osteoporosis of knee (off label use) [off label use of device].Drug use for unapproved indication [device use issue].Case (b)(4) is a serious spontaneous case received from a non-health professional via regulatory authority in united states.This report concerns a patient of unknown age and gender who had passed away during treatment with euflexxa (sodium hyaluronate) solution for injection 10 mg/ml, unknown dose and route of administration, for bilateral primary osteoporosis of knee (off label use of device [device use for unapproved indication]) from an unknown start date to an unknown stop date and the co-suspect drug synvisc one (hylan g-f 20) for an unknown indication on unknown dates.On (b)(6) 2019, the patient passed away.The reason for patient death was not reported.Action taken with euflexxa was not applicable.At the time of this report, the outcome of off label use of device and device use for unapproved indication were unknown.No concomitant medication was reported.At the time of reporting the case outcome was fatal.Overall listedness (core label) is unlisted.Reporter causality: not provided.Company causality: not related.Other case numbers: internal # - others = mw5088228.
|